Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in goldblatt hypertensive rats

Hypertension

Volumn 31, Issue 5, 1998, Pages 1104-1110

  Yayama, Katsutoshi ^a   Wang, Cindy ^a   Chao, Lee ^a   Chao, Julie ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Adenovirus; Blood pressure; Genetics; Hypertrophy, cardiac; Renal circulation

Indexed keywords

MESSENGER RNA; TISSUE KALLIKREIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SIZE; CONTROLLED STUDY; GENE TARGETING; GLOMERULUS FILTRATION RATE; HEART HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE CELL; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MALE; MICTURITION; NONHUMAN; PRIORITY JOURNAL; RAT; RENOVASCULAR HYPERTENSION; URINARY EXCRETION; VIRUS RECOMBINANT;

EID: 0031944079     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.31.5.1104     Document Type: Article

References (39)

1. Clements JA. The glandular kallikrein family of enzyme: tissue specific expression and hormonal regulation. Endocrine Rev. 1989;10:393-419.
2. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992;44:1-80.
3. Shimamoto K, Ura N, Tanaka S, Ogasawara A, Nakao T, Nakahashi Y, Chao J, Margolius HS, Iimura O. Excretion of human urinary kallikrein quantity measured by a direct radioimmunoassay of human urinary kallikrein in patients with essential hypertension and secondary hypertensive diseases. Jpn Circ J. 1981;45:1092-1097.
4. Berry TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash KO, Kuida H, Williams RR. A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension. 1989;13:3-8.
5. Margolius HS, Geller R, De Jong W, Pisano JJ, Sjoerdsma A. Altered urinary kallikrein excretion in rats with hypertension. Circ Res. 1972;30:358-362.
6. Favaro S, Baggio B, Antonello A, Zen A, Cannella G, Todesco S, Borsatti A. Renal kallikrein content of spontaneously hypertensive rats. Clin Sci Mol Med. 1975;49:69-71.
7. Chao J, Chai KX, Chen LM, Xiong W, Chao S, Woodley-Miller C, Wang LX, Lu HS, Chao L. Tissue kallikrein-binding protein is a serpin, I: purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem. 1990;265:16394-16401.
8. Overlack A, Stumpe KO, Kolloch R, Ressel C, Krueck F. Antihypertensive effect of orally administered glandular kallikrein in essential hypertension: results of double blind study. Hypertension. 1981;3(suppl I):I-18-I-21.
9. Wang J, Xiong W, Yang Z, Davis T, Dewey MJ, Chao J, Chao L. Human tissue kallikrein induces hypotension in transgenic mice. Hypertension. 1994;23:236-243.
10. Song Q, Chao J, Chao L. Liver-targeted expression of human tissue kallikrein induces hypotension in transgenic mice. Clin Exp Hypertens. 1996;18:975-993.
11. 2 receptor. Hypertension. 1997;29:488-493.
12. Wang C, Chao L, Chao J. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest. 1995;95:1710-1716.
13. Xiong W, Chao J, Chao L. Muscle delivery of human tissue kallikrein gene reduces blood pressure in spontaneously hypertensive rats. Hypertension. 1995;25:715-719.
14. Chao J, Jin L, Chen LM, Chen VC, Chao L. Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hum Gene Ther. 1996;7:901-911.
15. Chao J, Yang R, Jin L, Lin KF, Chao L. Kallikrein gene therapy in newborn and adult hypertensive rats. Can J Physiol Pharmacol. 1997;75:750-756.
16. Morton JJ, Wallace ECH. The importance of the renin-angiotensin system in the development and maintenance of hypertension in the two-kidney one-clip hypertensive rat. Clin Sci Land. 1983;64:359-370.
17. Ploth DW. Angiotensin-dependent renal mechanisms in two-kidney, one-clip renal vascular hypertension. Am J Physiol. 1983;245:F131-F141.
18. El-Dahr SS, Dipp S, Guan S, Navar LG. Renin, angiotensinogen, and kallikrein gene expression in 2K1C Goldblatt hypertensive rats. Am J Hypertens. 1993;6:914-919.
19. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory-Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989:7.12-7.22.
20. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res. 1994;74:349-353.
21. Shimamoto K, Tonaka S, Nakao T, Ando T, Nakahashi Y, Sakuma M, Miyahara M. Measurement of urinary kallikrein activity by kinin radioimmunoassay. Jpn Circ J. 1979;43:147-152.
22. Lin KF, Chao L, Chao J. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension. 1997;30:307-313.
23. Fitzgibbon WR, Jaffa AA, Mayfield RK, Ploth DW. Role of kinins in the renal response to enalaprilat in normotensive and hypertensive rats. Hypertension. 1996;27:235-244.
24. Leenen FHH, de Jong W, Wield D. Renal venous and peripheral plasma renin activity in renal hypertension in the rat. Am J Physiol. 1973;225:1513-1518.
25. Carretero OA, Gulati OP. Effects of angiotensin antagonists in rats with acute, subacute, and chronic two-kidney renal hypertension. J Lab Clin Med. 1978;91:264-271.
26. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
27. Romen RJ, Kaldunski ML, Scicli AG, Carretero OA. Influence of kinins and angiotensin II on the regulation of papillary blood flow. Am J Physiol. 1988;255:F690-F698.
28. Zinner SH, Margolius HS, Rosner B, Kass EH. Stability of blood pressure rank and urinary kallikrein concentration in childhood: an 8-year follow-up. Circulation. 1978;58:908-915.
29. Von Thun AM, el-Dahr SS, Vari RC, Navar LG. Modulation of renin-angiotensin and kallikrein gene expression in experimental hypertension. Hypertension. 1994;23(suppl I):I-131-I-136.
30. Girolami JP, Praddaude F, Ader JL, Tran Van T, Eche JP, Suc JM. Bilateral urinary kallikrein excretion in the Goldblatt hypertensive rat. Eur Heart J. 1983;4:67-72.
31. Bennett MA, Thurston H. Effect of angiotensin-converting enzyme inhibitors on resistance artery structure and endothelium-dependent relaxation in two-kidney, one-clip Goldblatt hypertensive and sham-operated rats. Clin Sci. 1996;90:21-29.
32. Lundgren Y, Weiss L. Cardiovascular design after 'reversal' of long-standing renal hypertension in rats. Clin Sci. 1979;57:19-21.
33. Linz W, Schölkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exper Hypertens. 1989;11:1325-1350.
34. Linz W, Schölkens BA. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol. 1992;20:S83-S90.
35. Beierwaltes WH, Carretero OA, Scicli AG. Renal hemodynamics in response to a kinin analogue antagonist. Am J Physiol. 1988;255:F408-F414.
36. Katori M, Majima M. Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship. Jpn J Pharmacol. 1996;70:95-128.
37. Huard J, Lochmuller H, Acsadi G, Jani A, Massie B, Karpati G. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 1995;2:107-115.
38. Jooss K, Yang Y, Wilson JM. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther. 1996;7:1555-1566.
39. Wang Q, Greenburg G, Bunch D, Farson D, Finer MH. Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔE1/ΔE4 adenovirus vector. Gene Ther. 1997;4:393-400.